Comments Off on FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of Nuplazid (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
SAN DIEGO–(BUSINESS WIRE)–Sep. 20, 2018– Acadia Pharmaceuticals Inc. (NASDAQ: ACAD)
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok